A phase II study of prostatic acid phosphatase-pulsed dendritic cells (Provenge) [sipuleucel T] in combination with bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Sipuleucel-T (Primary) ; Bevacizumab
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Aug 2007 Status changed from in progress to completed.
- 30 Sep 2005 New trial record.